Risk factors and outcomes in patients with carbapenem-resistant Acinetobacter infection

References

• Edis CE, Hatipoglu ON, Tansel O, Sut N. Acinetobacter pneumonia: is the outcome different from the pneumonias caused by other agents. Ann Thorac Med 2010;5:92–6.
   PubMed Web of Science ®Google Scholar
• Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, . Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 2010;10:228–38.
   PubMed Web of Science ®Google Scholar
• Navon-Venezia SH, Ronen Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005;18:306–13.
   PubMed Web of Science ®Google Scholar
• Erbay A, Idil A, Gözel MG, Mumcuoğlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents 2009;34:575–9.
   PubMed Web of Science ®Google Scholar
• Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009;20:540–4.
   PubMed Web of Science ®Google Scholar
• Lee SO, Kim NJ, Choi SH, Kim TH, Chung, Woo JH, . Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case–control study. Antimicrob Agents Chemother 2004;48:224–8.
   PubMed Web of Science ®Google Scholar
• Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, . Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother 2007;59:525–30.
   PubMed Web of Science ®Google Scholar
• Baran G, Erbay A, Bodur H, Onguru P, Akinci E, Balaban N, . Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Int J Infect Dis 2008;12:16–21.
   PubMed Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–32.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Approved standard M2-A9. 9^thed. Wayne, PA: CLSI; 2008.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
   PubMed Web of Science ®Google Scholar
• Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: a descriptive study in a city hospital. BMC Infect Dis 2010;10:196.
   PubMed Web of Science ®Google Scholar
• Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JK, . Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378–82.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Zembower T, Penugonda S, Schreckenberger P, Lavin MA, Welbel S, . Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak. Infect Control Hosp Epidemiol 2010;31:1057–62.
   PubMed Web of Science ®Google Scholar
• Prates CG, Martins AF, Superti SV, Lopes FS, Ramos F, Cantarelli VV, . Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit. Epidemiol Infect 2011;139:411–8.
   PubMed Web of Science ®Google Scholar
• Carbonne A, Naas T, Blanckaert K, Couzigou C, Cattoen C, Chagnon JL, . Investigation of a nosocomial outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a hospital setting. J Hosp Infect 2005;60:14–8.
   PubMed Web of Science ®Google Scholar
• Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, . Blood stream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27:607–12.
   PubMed Web of Science ®Google Scholar
• Caricato A, Montini L, Bello G, Michetti V, Maviglia R, Bocci MG, . Risk factors and outcome of Acinetobacter baumannii infection in severe trauma patients. Intensive Care Med 2009;35:1964–9.
   PubMed Web of Science ®Google Scholar
• Routsi C, Pratikaki M, Platsouka E, Sotiropoulou C, Nanas S, Markaki V, . Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010;38:173–80.
   PubMed Web of Science ®Google Scholar
• Huang ST, Chiang MC, Kuo SC, Lee YT, Chiang TH, Young SP, . Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2012;45:356–362.
   PubMedGoogle Scholar
• Aydemir H, Celebi G, Piskin N, Oztoprak N, Keskin AS, Aktas E, . Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Jpn J Infect Dis 2012;65:66–71.
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, . Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97–103.
   PubMed Web of Science ®Google Scholar
• Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65:204–11.
   PubMed Web of Science ®Google Scholar